Genentech
Roche
GO27826 |
This multi-center, randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of vemurafenib in patients with completely resected, cutaneous BRAF-mutation positive melanoma at high risk for recurrence. Patients will be randomized to receive oral doses of vemurafenib 960 mg twice daily or matching placebo.
Learn more.
|
NCT 01667419 |
BMS
CA184143 |
The purpose of this study is to examine the safety of Ipilimumab and patterns of use in the treatment of unresectable or metastatic melanoma in the post-approval setting.
Learn more.
|
NCT01511913 |
BMS
CA209037 |
The purpose of the study is to compare the response rate and overall survival of patients taking BMS-936558 to those taking study physician's choice of either Dacarbazine or Carboplatin and Paclitaxel.
Learn more.
|
NCT017221746 |
Genentech
Roche
GO28141 |
This multicenter, randomized, double-blind, placebo-controlled phase 3 study will evaluate the safety and efficacy of vemurafenib alone and vemurafenib in combination with GDC-0973, a MEK inhibitor, in previously untreated BRAF V600 mutation-positive patients with unresectable locally advanced or metastatic melanoma.
Learn more.
|
NCT01689519 |
CAMN
107B2301
SLHN
2010 -53 |
The TEAM Trial (Tasigna Efficacy in Advanced Melanoma): A Phase II, Open Label, Multi-center, Single-arm Study to Assess the Efficacy of Tasigna ® in the Treatment of Patients With Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Learn more.
|
NCT01028222 |
GO27826
SLHN
2012-62 |
Chemotherapy Toxicity in Elderly Women With Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Learn more.
|
NCT01366183 |
GO28141
SLHN
2012-97
ROCHE |
A Study of Vemurafenib Alone And Vemurafenib in Combination With GDC-0973 in Patients With Malignant Melanoma
Learn more.
|
NCT01689519 |
ZIOPHARM
AT 1001 101
SLHN
2012- 86 |
A Phase I/II, Open Label Study of Ad-RTS-hIL-12, an Adenovirus Vector Engineered to Express hIL-12, in Combination With an Oral Activator Ligand, in Subjects With Unresectable Stage III or IV Melanoma
Learn more.
|
NCT01397708 |
MERCK
3475 002
SLHN
2012-77 |
Randomized, Phase II Study of MK-3475 Versus Chemotherapy in Patients With Advanced Melanoma
Learn more.
|
NCT01704287 |
Prometheus
12PLK01 |
A Multi-Center Study of High Dose Aldesleukin (Interleukin-2) + Vemurafenib Therapy in Patients With BRAFV600 Mutation Positive Metastatic Melanoma
Learn more.
|
NCT01683188 |
ECOG
2607 |
A Phase II Trial of Dasatinib in Patients with Unresectable Locally Advanced or Stage IV Mucosal, Acral, and Solar Melanomas
Learn more.
|
NCT00700882 |
ECOG
1609 |
A Phase III Randomized Study of Adjuvant Ipilimimab Anti-CTLA4 Therapy vs. High-Dose Interferon Alpha-2b for Resected High Risk Melanoma
Learn more.
|
NCT01274338 |
|
SLHN
2009-84
Provectus
PV10-
EA02
|
Open Label Expanded Access for Investigational Use of PV-10 in Patients who are not Eligible for an Existing PV-10 Clinical Trial for whom there is no Comparable or Satisfactory Approved Alternative Therapy & Whom in the Opinion of the Investigator may Benefit from PV-10 Administration |
|
SLHN
2005-22
MSLT-II |
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection versus Sentinel Lymphadenectomy alone in Cutaneous Melanoma Patients with Molecular or Histopatholgical Evidence of Metastases in the Sentinel Node
Learn more.
|
NCT00297895 |